Atea Pharmaceuticals Highlights Phase 3 HCV Timeline, Unveils New Hepatitis E Candidate AT-587 at JPMorgan Conference

Atea Pharmaceuticals (NASDAQ:AVIR) used its presentation at the 44th Annual JPMorgan Healthcare Conference to provide updates ...
Nasdaq

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America

C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class ...
Healio

Measurements for HCV cure could be done earlier among people who inject drugs

People with hepatitis C virus who inject drugs could be evaluated for cure approximately 2 months earlier than current ...
Nasdaq

Atea Pharmaceuticals Reports Successful FDA Meeting and Plans Phase 3 Program for Hepatitis C Treatment

Atea Pharmaceuticals announced a successful End-of-Phase 2 meeting with the FDA and plans to start patient enrollment for its global Phase 3 program for treating hepatitis C virus (HCV) in April 2025.